About Brawn Biotech Limited
Data last updated:
Brawn Biotech Limited is a public limited company based in Delhi, Delhi, India. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 07 November 1985, the company has been in operation for over 41 years.
Registered with ROC Delhi under CIN L74899DL1985PLC022468. Listed on BSE: 530207.
Capital: an authorised share capital of ₹4.5 Cr and a paid-up capital of ₹3 Cr. Formerly known as Brawn Pharmaceuticals Limited and Brawn Pharmaceuticals Private Limited. It is led by directors including Brij Raj Gupta and Mayank Jain.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: First Floor C – 64 Lagpat Nagar – 1, Delhi, Delhi, India – 110024.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹16.98 Cr, a growth of 26.15% compared to the previous year. The net worth stands at ₹4.34 Cr (up 29.17% YoY). Total assets are valued at ₹5.69 Cr (down 49.01% YoY).
The company is associated with 2 brands - Brawnpharma, Brawn Biotech. As per MCA filings, the company has satisfied charges of ₹30.28 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website brawnbiotech.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressFirst Floor C – 64 Lagpat Nagar – 1, Delhi, Delhi, India – 110024
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Brawn Biotech
Brawn Biotech has undergone 4 name changes throughout its history. The current legal name is Brawn Biotech Limited.
| Company Name | Status |
|---|---|
| Brawn Biotech Limited | Current |
| Brawn Pharmaceuticals Limited | Previous |
| Brawn Pharmaceuticals Private Limited | Previous |
| Brawn Pharmaceuticals Ltd | Previous |
| Brawn Pharmaceuticals P Ltd | Previous |
Associated Brands with Brawn Biotech
Brawn Biotech operates two associated brands: Brawnpharma and Brawn Biotech. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical formulations are distributed across major healthcare segments. | brawnbiotech.com | |
| Pharmaceutical products are developed and distributed by Brawnpharma. | brawnpharma.com |
Competitors & Alternatives of Brawn Biotech
Brands and companies operating in the same space as Brawn Biotech Limited include Entero Healthcare, AmerisourceBergen, Keimed and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
 Entero Healthcare | India's leading healthcare products distribution platform | Mumbai, India, India | 2018 |
 AmerisourceBergen | Pharmaceutical distribution and supply chain services are provided globally. | Chesterbrook, United States, United States | 1985 |
 Keimed | Temperature-sensitive medicines are distributed via cold chain logistics by Keimed. | Hyderabad, India, India | 2000 |
 Sandor Medicaids | Provider of medical equipment, devices, and drugs distribution services | Hyderabad, India, India | 1995 |
 Dipna Pharmachem | Distributor of pharmaceutical raw materials | Ahmedabad, India, India | 2011 |
 Mahaveer Medi Sales | Serves as a distributor of a wide range of pharmaceutical drugs. | Bengaluru, India, India | 2016 |
 Salas Pharmaceuticals | A healthcare company specializing in multidisciplinary engineering and technical services. | Patna, India, India | 2009 |
 Kaushal Pharma | Distributes pharmaceuticals to over 1500 retailers and wholesalers in Kolkata. | Kolkata, India, India | 1970 |
Business Activity of Brawn Biotech
The main business activity of Brawn Biotech is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details for Brawn Biotech Limited
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Brawn Biotech
Brawn Biotech Limited is audited by RAJIV UDAI AND ASSOCIATES for the financial year 2022.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| RAJIV UDAI AND ASSOCIATES | Locked | Locked | Locked |
Complete auditor history for Brawn Biotech Limited
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Brawn Biotech Limited
Brawn Biotech has 3 current directors and 19 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Brij Raj Gupta | Director | 07 Nov 1985 | 40 Years 10 Months | Current |
| Mayank Jain | Director | 27 Aug 2024 | 2 Years 1 Months | Current |
| Pooja Jha Also directs: Brawn Laboratories Limited | Director | 27 Aug 2024 | 2 Years 1 Months | Current |
Financials of Brawn Biotech Limited FY 2025-26 filings available
Brawn Biotech Limited reported revenue of ₹16.98 Cr (up 26.15% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 16.98 | 13.46 | 16.49 | 22.23 | 8.62 | 34.98 | 49.62 |
| Revenue growth | +13.5% | -15.1% | -20.3% | +112.1% | -70.1% | -27.2% | -23.6% |
| EBITDA | (0.31) | (1.78) | (1.47) | (0.29) | (2.00) | (0.59) | 0.74 |
| EBITDA margin | -1.8% | -13.2% | -8.9% | -1.3% | -23.2% | -1.7% | +1.5% |
| Profit before tax | 0.02 | (1.80) | (1.54) | (0.40) | (2.11) | (0.35) | 0.83 |
| Net profit | 0.96 | (1.74) | (1.23) | (0.85) | (1.64) | (0.55) | 0.60 |
| Net profit margin | +5.7% | -12.9% | -7.5% | -3.8% | -19.0% | -1.6% | +1.2% |
| EPS (₹) | 3.14 | (5.80) | (4.16) | (2.89) | (5.48) | (1.84) | 1.97 |
| Balance sheet | |||||||
| Total assets | 5.69 | 11.16 | 8.08 | 6.48 | 7.46 | 8.97 | 9.37 |
| Net worth | 4.34 | 3.36 | 5.06 | 6.31 | 7.22 | 8.79 | 9.26 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 0.28 | 0.20 | 0.40 | 0.44 | 0.22 | 0.40 | 0.40 |
| Net working capital | 1.95 | 8.18 | 6.63 | 5.35 | 5.86 | 7.83 | 8.29 |
| Cash flow | |||||||
| Cash from operations | 0.77 | 0.05 | (0.03) | 0.32 | 0.19 | 0.03 | (0.08) |
| Cash from investing | (0.03) | (0.24) | (0.01) | (0.10) | (0.30) | 0.00 | (0.02) |
| Cash from financing | 0.00 | 0.00 | 0.00 | (0.01) | (0.06) | (0.04) | (0.05) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.08 | 1.98 | 4.31 | 4.89 | 5.80 | 2.26 | 3.84 | 3.30 |
| Revenue growth (YoY) | +4.8% | -12.4% | +12.2% | +48.2% | +42.9% | -34.5% | +35.2% | +13.0% |
| Other income | 0.14 | 0.18 | 0.09 | 0.09 | 0.09 | 0.09 | 0.00 | 0.00 |
| Total expenses | 6.03 | 2.48 | 4.32 | 4.88 | 5.62 | 2.81 | 4.25 | 3.61 |
| EBITDA | 0.05 | (0.50) | (0.01) | 0.01 | 0.18 | (0.55) | (0.41) | (0.31) |
| EBITDA margin | +0.8% | -25.3% | -0.2% | +0.2% | +3.1% | -24.3% | -10.7% | -9.4% |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.16 | (0.35) | 0.05 | 0.07 | 0.24 | (0.49) | (0.44) | (0.34) |
| Tax | 0.00 | (0.94) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.08 | 1.98 | 4.31 | 4.89 | 5.80 | 2.26 | 3.84 | 3.30 |
| Revenue growth (YoY) | +4.8% | -12.4% | +12.2% | +48.2% | +42.9% | -34.5% | +35.2% | +13.0% |
| Other income | 0.14 | 0.18 | 0.09 | 0.09 | 0.09 | 0.09 | 0.00 | 0.00 |
| Total expenses | 6.03 | 2.48 | 4.32 | 4.88 | 5.62 | 2.81 | 4.25 | 3.61 |
| EBITDA | 0.05 | (0.50) | (0.01) | 0.01 | 0.18 | (0.55) | (0.41) | (0.31) |
| EBITDA margin | +0.8% | -25.3% | -0.2% | +0.2% | +3.1% | -24.3% | -10.7% | -9.4% |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.16 | (0.35) | 0.05 | 0.07 | 0.24 | (0.49) | (0.44) | (0.34) |
| Tax | 0.00 | (0.94) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 16.98 | 13.46 | 16.49 | 22.23 | 8.62 | 34.98 | 49.62 |
| Revenue growth | +13.5% | -15.1% | -20.3% | +112.1% | -70.1% | -27.2% | -23.6% |
| Other income | 0.45 | 0.09 | 0.09 | 0.01 | 0.00 | 0.31 | 0.17 |
| Total expenses | 17.29 | 15.24 | 17.96 | 22.52 | 10.62 | 35.57 | 48.88 |
| Employee cost | 0.68 | 1.13 | 1.40 | 1.40 | 1.80 | 2.36 | 3.08 |
| EBITDA | (0.31) | (1.78) | (1.47) | (0.29) | (2.00) | (0.59) | 0.74 |
| EBITDA margin | -1.8% | -13.2% | -8.9% | -1.3% | -23.2% | -1.7% | +1.5% |
| Depreciation | 0.12 | 0.11 | 0.10 | 0.11 | 0.05 | 0.03 | 0.03 |
| Interest | 0.00 | 0.00 | 0.06 | 0.01 | 0.06 | 0.04 | 0.05 |
| Profit before tax | 0.02 | (1.80) | (1.54) | (0.40) | (2.11) | (0.35) | 0.83 |
| Tax | (0.94) | (0.06) | (0.30) | 0.45 | (0.47) | 0.20 | 0.23 |
| Net profit | 0.96 | (1.74) | (1.23) | (0.85) | (1.64) | (0.55) | 0.60 |
| Net profit margin | +5.7% | -12.9% | -7.5% | -3.8% | -19.0% | -1.6% | +1.2% |
| EPS (₹) | 3.14 | (5.80) | (4.16) | (2.89) | (5.48) | (1.84) | 1.97 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| Reserves & surplus | 1.34 | 0.36 | 2.06 | 3.31 | 4.22 | 5.79 | 6.26 |
| Shareholders' funds (net worth) | 4.34 | 3.36 | 5.06 | 6.31 | 7.22 | 8.79 | 9.26 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 5.69 | 11.16 | 8.08 | 6.48 | 7.46 | 8.97 | 9.37 |
| Assets | |||||||
| Gross block | 1.05 | 1.02 | 0.78 | 0.77 | 0.67 | 0.38 | 0.38 |
| Net block | 0.36 | 0.46 | 0.33 | 0.37 | 0.38 | 0.14 | 0.18 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 10.06 | 10.47 | 6.02 | 4.79 | 4.72 | 0.26 | 0.39 |
| Sundry debtors | 3.55 | 3.41 | 3.88 | 5.32 | 2.81 | 9.28 | 15.00 |
| Cash & bank balances | 0.28 | 0.20 | 0.40 | 0.44 | 0.22 | 0.40 | 0.40 |
| Loans & advances | 3.23 | 3.43 | 2.84 | 2.85 | 4.43 | 2.79 | 3.42 |
| Total current assets | 17.12 | 17.51 | 13.14 | 13.40 | 12.18 | 12.73 | 19.21 |
| Total current liabilities | 15.17 | 9.33 | 6.51 | 8.05 | 6.32 | 4.90 | 10.92 |
| Net working capital | 1.95 | 8.18 | 6.63 | 5.35 | 5.86 | 7.83 | 8.29 |
| Total assets | 5.69 | 11.16 | 8.08 | 6.48 | 7.46 | 8.97 | 9.37 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.20 | 0.00 | 0.44 | 0.22 | 0.40 | 0.40 | 0.54 |
| Net cash from operating activities | 0.77 | 0.05 | (0.03) | 0.32 | 0.19 | 0.03 | (0.08) |
| Net cash from investing activities | (0.03) | (0.24) | (0.01) | (0.10) | (0.30) | 0.00 | (0.02) |
| Net cash from financing activities | 0.00 | 0.00 | 0.00 | (0.01) | (0.06) | (0.04) | (0.05) |
| Net change in cash | 0.74 | (0.20) | (0.04) | 0.21 | (0.17) | 0.00 | (0.14) |
| Closing cash | 0.28 | 0.20 | 0.40 | 0.44 | 0.22 | 0.40 | 0.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +26.2% | -18.4% | -25.8% | +157.9% | -75.4% | -29.5% | -23.9% |
| EBITDA growth | +82.6% | -21.1% | -406.9% | +85.5% | -239.0% | - | -37.3% |
| PBT growth | +9998.0% | -16.9% | -285.0% | +81.0% | -502.9% | - | -54.4% |
| Net income growth | +9998.0% | -41.5% | -44.7% | +48.2% | -198.2% | - | -55.2% |
| Revenue CAGR (3Y) | -8.6% | +16.0% | -22.2% | -23.5% | -49.1% | -14.4% | -6.4% |
| EBITDA CAGR (3Y) | +2.3% | -3.8% | +35.6% | - | - | - | -15.6% |
| Profitability & leverage | |||||||
| Net income margin | +5.7% | -12.9% | -7.5% | -3.8% | -19.0% | -1.6% | +1.2% |
| Return on capital employed | 0.0% | 0.0% | -20.5% | -5.7% | -25.0% | -3.5% | +9.6% |
| Return on net worth | +22.2% | 0.0% | -22.0% | -12.9% | -20.5% | -6.1% | +6.6% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | -3.82 | -2.50 | -2.93 | -6.45 | 7.04 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 16.41 | 14.96 | 21.28 | 30.88 | 16.42 | 92.05 | 132.32 |
| Inventory turnover | 1.65 | 1.63 | 3.05 | 4.68 | 3.46 | 107.63 | 135.95 |
| Debtors turnover | 4.88 | 3.69 | 3.58 | 5.47 | 1.43 | 2.88 | 3.15 |
| EPS (₹) | 3.14 | (5.80) | (4.16) | (2.89) | (5.48) | (1.84) | 1.97 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 14.46 | 11.21 | 16.88 | 21.03 | 24.07 | 29.31 | 30.87 |
Shareholding Pattern of Brawn Biotech Limited
Shareholding for the quarter ended Mar 2026: promoters hold 52.90%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.40% and retail and other public shareholders hold 46.70%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 52.90% | 53.40% | 53.70% | 53.70% |
| Public | 47.10% | 46.60% | 46.30% | 46.30% |
Charges & Borrowings of Brawn Biotech
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Apr 2015 | Punjab National Bank | ₹6.74 Lakh | Satisfied |
| 21 Apr 2015 | Punjab National Bank | ₹6.74 Lakh | Satisfied |
| 09 Apr 2014 | Punjab National Bank | ₹14.6 Lakh | Satisfied |
| 01 Sep 2011 | Punjab National Bank | ₹2.2 Lakh | Satisfied |
Total charge records: 4 View all charges
Employees and EPFO Compliance at Brawn Biotech
Employment history and EPFO contributions of people linked to Brawn Biotech.
Employee and EPFO history for Brawn Biotech Limited
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Brawn Biotech
GST registrations and filing compliance for Brawn Biotech Limited
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Brawn Biotech
Credit ratings, litigation, and regulatory alerts for Brawn Biotech Limited
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Brawn Biotech
MSME payment history for Brawn Biotech Limited
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Brawn Biotech
Corporate group structure for Brawn Biotech Limited
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Brawn Biotech
MCA filings and documents for Brawn Biotech Limited
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Brawn Biotech
Frequently Asked Questions about Brawn Biotech Limited
Brawn Biotech is an active public limited company in the pharma sector based in Delhi, Delhi, India. It was incorporated on 07 November 1985 (41+ years old) and is registered under CIN L74899DL1985PLC022468. Listed on BSE: 530207.
Brawn Biotech reported revenue of ₹16.98 Cr for FY 2025-26 (up 26.15% YoY) based on standalone financials.
The current directors of Brawn Biotech are:
- Brij Raj Gupta - Director
- Mayank Jain - Director
- Pooja Jha - Director
The primary industry of Brawn Biotech is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Yes. Brawn Biotech is listed on BSE with code 530207.
Brawn Biotech can be reached at the registered office: First Floor C – 64 Lagpat Nagar – 1, Delhi, Delhi, India – 110024, or through the website brawnbiotech.com.